Skip to main content
SpringerLink
Log in

Drug Interactions with Antiviral Drugs

  • Review Article
  • Drug Interactions
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Summary

Antiviral drug interactions are a particular problem among immuno-compromised patients because these patients are often receiving multiple different drugs, i.e. antiretroviral drugs and drugs effective against herpesvirus. The combination of zidovudine and other antiretroviral drugs with different adverse event profiles, such as didanosine, zalcitabine and lamivudine, appears to be well tolerated and no relevant pharmacokinetic interactions have been detected. The adverse effects of didanosine and zalcitabine (i.e. peripheral neuropathy and pancreatitis) should be taken into account when administering these drugs with other drugs with the same tolerability profile.

Coadministration of zidovudine and ganciclovir should be avoided because of the high rate of haematological intolerance. In contrast, zidovudine and foscarnet have synergistic effect and no pharmacokinetic interaction has been detected. No major change in zidovudine pharmacokinetics was seen when the drug was combined with aciclovir, famciclovir or interferons. However, concomitant use of zidovudine and ribavirin is not advised.

Although no pharmacokinetic interaction was documented when didanosine was first administered with intravenous ganciclovir, recent studies have shown that concentrations of didanosine are increased by 50% or more when coadministered with intravenous or oral ganciclovir. The mechanism of this interaction has not been elucidated. Lack of pharmacokinetic interaction was demonstrated between foscarnet and didanosine or ganciclovir.

Clinical trials have shown that zidovudine can be administered safely with paracetamol (acetaminophen), nonsteroidal anti-inflammatory drugs, oxazepam or codeine. Inhibition of zidovudine glucuronidation has been demonstrated with fluconazole, atovaquone, valproic acid (valproate sodium), methadone, probenecid and inosine pranobex; however, the clinical consequences of this have not been fully investigated.

No interaction has been demonstrated with didanosine per se but care should be taken of interaction with the high pH buffer included in the tablet formulation. Drugs that need an acidic pH for absorption (ketoconazole, itraconazole but not fluconazole, dapsone, pyrimethamine) or those that can be chelated by the ions of the buffer (quinolones and tetracyclines) should be administered 2 hours before or 6 hours after didanosine.

Very few interaction studies have been undertaken with other antiviral drugs. Coadministration of zalcitabine with the antacid ‘Maalox’ results in a reduction of its absorption. Dapsone does not influence the disposition of zalcitabine. Cotrimoxazole (trimethoprim-sulfamethoxazole) causes an increase in lamivudine concentrations by 43%. Saquinavir, delavirdine and atevirdine appeared to be metabolised by cytochrome P450 and interactions with enzyme inducers or inhibitors could be anticipated.

Some studies showed that interferons can reduce drug metabolism but only a few studies have evaluated the pathways involved.

Further studies are required to better understand the clinical consequences of drug interactions with antiviral drugs. Drug-drug interactions should be considered in addition to individual drug clinical benefits and safety profiles.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fogelman I, Lim L, Bassett R, et al. Prevalence and patterns of use of concomitant medications among participants in three multicenter human immunodeficiency virus type I clinical trials. J Acquir Immune Defic Syndr 1994; 7: 1057–63

    PubMed  CAS  Google Scholar 

  2. Darbyshire J. Perspectives in drug therapy of HIV infection. Drugs 1995; 49: 1–3

    Article  PubMed  Google Scholar 

  3. Coleman R. Overview of antiretroviral therapy. Pharmacotherapy 1994; 14 Suppl.: 3S–8S

    PubMed  CAS  Google Scholar 

  4. Wills RJ. Clinical pharmacokinetics of interferons. Clin Pharmacokinet 1990; 19: 390–9

    Article  PubMed  CAS  Google Scholar 

  5. Morse GD, Shelton MJ, O’Donnell AM. Comparative pharmacokinetics of antiviral nucleoside analogues. Clin Pharmacokinet 1993; 24: 101–23

    Article  PubMed  CAS  Google Scholar 

  6. Campoli-Richards DM, Sorkin E, Heel RC. Inosine Pranobex: a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs 1986; 32: 383–424

    Article  PubMed  CAS  Google Scholar 

  7. Aoki FY, Sitar DS. Clinical pharmacokinetics of amantadine hydrochloride. Clin Pharmacokinet 1988; 14: 35–51

    Article  PubMed  CAS  Google Scholar 

  8. Mayers DL. Zidovudine and other antiretroviral agents including drug interactions and toxicities. Curr Opin Infect Dis 1993; 6: 210–7

    Article  Google Scholar 

  9. Morris DJ. Adverse effects and drug interactions of clinical importance with antiviral drugs. Drug Saf 1994; 10: 281–91

    Article  PubMed  CAS  Google Scholar 

  10. Quinn DI, Day RO. Drug interactions of clinical importance: an updated guide. Drug Saf 1995; 12: 393–452

    Article  PubMed  CAS  Google Scholar 

  11. Wilde MI, Langtry HD. Zidovudine: an update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1993; 46: 515–78

    Article  PubMed  CAS  Google Scholar 

  12. Dudley MN. Clinical pharmacokinetics of nucleoside antiretroviral agents. J Infect Dis 1995; 7 Suppl.: S99–S112

    Article  Google Scholar 

  13. Shelton MJ, O’Donnell AM, Morse GD. Didanosine. Ann Pharmacother 1992; 26: 660–700

    PubMed  CAS  Google Scholar 

  14. Faulds D, Brogden RN. Didanosine: a review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection. Drugs 1992; 44: 94–116

    Article  PubMed  CAS  Google Scholar 

  15. Devinemi D, Gallo JM. Zalcitabine: clinical pharmacokinetics and efficacy. Clin Pharmacokinet 1995; 28: 351–60

    Article  Google Scholar 

  16. Whittington R, Brogden RN. Zalcitabine, a review of its pharmacology and clinical potential in acquired immunodefiency syndrome (AIDS). Drugs 1992; 44: 656–83

    Article  PubMed  CAS  Google Scholar 

  17. Placidi L, Cretton E, Placidi M, et al. Reduction of 3′-azido-3′-deoxythymidine to 3′-amino-3′-deoxythymidine in human liver microsomes and its relationship to cytochrome P 450. Clin Pharmacol Ther 1993; 54: 168–76

    Article  PubMed  CAS  Google Scholar 

  18. Borin MT, Cox SR, Chambers JH, et al. Effect of rifampicin on delavirdine pharmacokinetics in HIV-positive patients [abstract no. A50]. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1994 Oct 4–7: Orlando

  19. Borin MT, Cox SR, Driver MR, et al. Effect of rifabutin on delavirdine pharmacokinetics in HIV-positive patients [abstract no. A48]. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1994 Oct 4–7: Orlando

  20. Farrar G, Mitchell AM, Hooper H, et al. Prediction of potential drug interactions of saquinavir (Ro 31 -8959) from in vitro data [abstract]. Br J Clin Pharmacol 1994; 38: 162P

    Google Scholar 

  21. Wagstaff AJ, Faulds D, Goa KL. Aciclovir: a reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994; 47: 153–205

    Article  PubMed  CAS  Google Scholar 

  22. Markham A, Faulds D. Ganciclovir: an update of its therapeutic use in cytomegalovirus infection. Drugs 1994; 48: 455–84

    Article  PubMed  CAS  Google Scholar 

  23. Wagstaff AJ, Bryson HM. Foscarnet: a reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs 1994; 48: 199–226

    Article  PubMed  CAS  Google Scholar 

  24. Daniels S. Schentag JJ. Drug interaction studies and safety of famciclovir in healthy volunteers: a review. Antiviral Chem Chemother 1993; 4 Suppl. 1: 57–64

    CAS  Google Scholar 

  25. Fowles SE, Pierce DM, Prince WT, et al. The tolerance to and pharmacokinetics of penciclovir, a novel antiherpes agent, administered by intravenous infusion to healthy volunteers. Eur J Clin Pharmacol 1992; 43: 513–6

    Article  PubMed  CAS  Google Scholar 

  26. Boike SC, Pue M, Audet PR, et al. Pharmacokinetics of famciclovir in subjects with chronic hepatic disease. J Clin Pharmacol 1994; 34: 1199–207

    PubMed  CAS  Google Scholar 

  27. Weiler S, Blum R, Doucette M, et al. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single and multiple-dose administration to normal volunteers. Clin Pharmacol Ther 1993; 54: 595–605

    Article  Google Scholar 

  28. Sim SM, Back DJ, Breckenridge AM. The effect of various drugs on the glucuronidation of zidovudine (azidothymidine, AZT) by human liver microsomes. Br J Clin Pharmacol 1991; 32: 17–21

    Article  PubMed  CAS  Google Scholar 

  29. Rajaonarison JF, Lacarelle B, Catalin J, et al. 3′-azido-3′-deoxythymidine drug interactions. Drug Metab Dispos 1992; 20: 578–84

    PubMed  CAS  Google Scholar 

  30. Barry M, Howe L, Ormesher S, et al. Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome. Br J Clin Pharmacol 1994; 37: 421–6

    Article  PubMed  CAS  Google Scholar 

  31. Sahai J, Gallicano K, Seguin I, et al. Interaction between zidovudine and didanosine [abstract no. A60]. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1994 Oct 4–7: Orlando

  32. Collier AC, Coombs RW, Fischl MA, et al. Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection. Ann Intern Med 1993; 119: 786–93

    PubMed  CAS  Google Scholar 

  33. Mueller BU, Pizzo PA, Farley M, et al. Pharmacokinetic evaluation of the combination of zidovudine and didanosine in children with human immunodeficiency virus infection. J Pediatr 1994; 125: 142–6

    Article  PubMed  CAS  Google Scholar 

  34. Qian M, Swagler AR, Mehta M, et al. Pharmacokinetic evaluation of drug interactions with anti-human immunotrophic virus (HIV) drugs. III. 2′, 3′-Dideoxycytidine (ddC) and zidovudine in monkeys. Pharm Res 1992; 9: 224–7

    Article  PubMed  CAS  Google Scholar 

  35. Meng TC, Fischl MA, Boota AM, et al. Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. Ann Intern Med 1992; 116: 13–20

    PubMed  CAS  Google Scholar 

  36. Fischl MA, Stanley K, Collier AC, and the NIAID AIDS Clinical Trials Group. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. Ann Intern Med 1995; 122: 24–32

    PubMed  CAS  Google Scholar 

  37. Veal GJ, Wild MJ, Barry MG, et al. Effects of dideoxyinosine and dideoxycytidine on the intracellular phosphorylation of zidovudine in human mononuclear cells. Br J Clin Pharmacol 1994; 38: 323–8

    Article  PubMed  CAS  Google Scholar 

  38. Rana KZ, Horton CM, Yuen GJ, et al. Effect of lamivudine on zidovudine pharmacokinetics in asymptomatic HIV infected individuals [abstract no. A26]. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1994 Oct 4–7; Orlando

  39. Horton CM, Yuen G, Mikolich DM, et al. Pharmacokinetics of oral lamivudine administered alone and with oral zidovudine in asymptomatic patients with human immuno-deficiency virus infection. Clin Pharmacol Ther 1994; 55: 198

    Google Scholar 

  40. Collier AC, Coombs RW, Timpone J, et al. Comparative study of Ro 31-8959 and zidovudine (ZDV) vs ZDV and zalcitabine (ddC) vs Ro 31-8959, ZDV and ddC [abstract no. 058B]. 10th International Conference on AIDS: 1994 Aug 7–12; Yokohama

  41. Vella S. Update on a proteinase inhibitor. AIDS 1994; 8 (Suppl.): S25–S29

    Article  PubMed  Google Scholar 

  42. Johnson VA. Combination therapy: more effective control of HIV type 1? AIDS Res Hum Retroviruses 1994; 10: 907–12

    Article  PubMed  CAS  Google Scholar 

  43. LeLacheur SF, and Simon GL, et al. Exacerbation of dideoxycytidine induced neuropathy with dideoxyinosine. J Acquir Immune Defic Syndr 1991; 4: 538–9

    PubMed  CAS  Google Scholar 

  44. Scifert RD, Stewart MB, Sramek JJ, et al. Pharmacokinetics of co-administered didanosine and stavudine in HIV-seropositive male patients. Br J Clin Pharmacol 1994; 38: 405–10

    Article  Google Scholar 

  45. Morse GD, Fischl MA, Cox SR, et al. Effect of didanosine on the single dose pharmacokinetics of delavirdine in HIV-positive patients [abstract no. A52]. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1994 Oct 4–7; Orlando

  46. Shelton MJ, Morse GD, Borin MT, et al. Didanosine reduces atevirdine absorption [abstract no. A56]. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1994 Oct 4–7; Orlando

  47. Hochster H, Dieterich D, Bozzette S, et al. Toxicity of combined ganciclovir and zidovudine for cytomegalovirus disease associated with AIDS. Ann Intern Med 1990; 113: 111–7

    PubMed  CAS  Google Scholar 

  48. Burger DM, Meenhorst PL, Koks CHW, et al. Drugs interactions with zidovudine. AIDS 1993; 7: 445–60

    Article  PubMed  CAS  Google Scholar 

  49. Burger DM, Meenhorst PL, Ten Napel CHH, et al. Pharmacokinetic variability of zidovudine in HIV-infected individuals: subgroup analysis and drug interactions. AIDS 1994; 8: 1683–9

    Article  PubMed  CAS  Google Scholar 

  50. Gaines K, Wong R, Jung D, et al. Pharmacokinetic interactions with oral ganciclovir: zidovudine, didanosine, probenecid [abstract no. 4B]. Xth International Conference on AIDS: 1994 Aug 7–12; Yokohama

  51. Gowland PL, Kuster H, Nadai V, et al. Ganciclovir reduces the amount of intracellular zidovudine phosphorylation products [abstract no. 2218]. IXth International Conference on AIDS: 1993 Jun 6–11; Berlin

  52. Jacobson MA, Van Der Horst C, Causey DM, et al. In vivo additive antiretroviral effect of combined zidovudine and foscarnet therapy for human immunodeficiency virus infection (ACTG protocol 053). J Infect Dis 1991; 63: 1219–22

    Article  Google Scholar 

  53. Aweeka FT, Gambertogkio JG, Van Der Horst C, et al. Pharmacokinetics of concomitantly administered foscarnet and zidovudine for treatment of human immunodeficiency virus infection (AIDS clinical trials group protocol 053). Anti-microb Agents Chemother 1992; 36: 1773–8

    Article  CAS  Google Scholar 

  54. Hollander H, Lifson AR, Maha M, et al. Phase I study of low-dose zidovudine and acyclovir in asymptomatic human immunodeficiency virus-seropositive individuals. Am J Med 1989; 87: 628–32

    Article  PubMed  CAS  Google Scholar 

  55. Stein DS, Graham NMH, Park LP, et al. The effect of the interaction of acyclovir with zidovudine on progression to AIDS and survival. Ann Intern Med 1994; 121: 100–8

    PubMed  CAS  Google Scholar 

  56. Rousseau F, Scott S, Pratt S, et al. Safe coadministration of famciclovir and zidovudine [abstract no. A64]. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1994 Oct 4–7; Orlando

  57. Nokta M, Loh JP, Douidar SM, et al. Metabolic interaction of recombinant interferon-β and zidovudine in AIDS patients. J Interferon Res 1991; 11: 159–64

    Article  PubMed  CAS  Google Scholar 

  58. Jacobson MA, Owen W, Campbell J, et al. Tolerability of combined ganciclovir and didanosine for the treatment of cytomegalovirus disease associated with AIDS. Clin Infect Dis 1993; 16: S69–S73

    Article  PubMed  Google Scholar 

  59. Hartman NR, Yarchoan R, Pluda JM, et al. Pharmacokinetics of 2′, 3′-dideoxyinosine in patients with severe human immunodeficiency infection: II. The effects of different oral formulations and the presence of other medications. Clin Pharmacol Ther 1991; 50: 278–85

    Article  PubMed  CAS  Google Scholar 

  60. Frascino RJ, Anderson RD, Gaines Griffy K, et al. Two multiple dose crossover studies of IV ganciclovir (GCV) and didanosine (ddI) in HIV infected persons [abstract no. A27]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1995 Sep 17–20; San Francisco

  61. Trapnell CB, Cimoch P, Gaines K, et al. Altered didanosine pharmacokinetics with concomitant oral ganciclovir. Clin Pharmacol Ther 1994; 55: 193

    Google Scholar 

  62. Aweeka FT, Mathur V, Dorsey R, et al. Pharmacokinetics of concomitant foscarnet and didanosine in patients with HIV disease. Clin Pharmacol Ther 1995; 57: 143

    Article  Google Scholar 

  63. Aweeka FT, Gambertoglio JG, Van Der Host C, et al. Pharmacokinetics of foscarnet during alternating vs concomitant ganciclovir maintenance therapy for CMV retinitis. Clin Pharmacol Ther 1993; 53: 278

    Google Scholar 

  64. Gillum JG, Israel DS, Polk RE. Pharmacokinetic drug interactions with antimicrobial agents. Clin Pharmacokinet 1993; 25: 450–82

    Article  PubMed  CAS  Google Scholar 

  65. Narang PK, Sale M. Population based assessment of rifabutin effect on zidovudine disposition in AIDS patients. Clin Pharmacol Ther 1993; 53: 219

    Google Scholar 

  66. Sahai J, Gallicano K, Pakuts A, et al. Effect of fluconazole on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus. J Infect Dis 1994; 169: 1103–7

    Article  PubMed  CAS  Google Scholar 

  67. Lee BL, Tauber MG, Sadler B, et al. Atovaquone inhibits the glucuronidation and increases the serum concentrations of zidovudine. Clin Pharmacol Ther 1996; 59: 14–21

    Article  PubMed  CAS  Google Scholar 

  68. Jatlow P, McCance EF, Rainey PM, et al. Methadone increases zidovudine exposure in HIV-infected injection drug users (ACTG 262) [abstract no. 405]. 3rd Conference on retro-viruses and opportunistic infections: 1996 Jun 28–Feb 1; Washington

  69. De Simone C, Tzantzoglou S, Vullo V, et al. Inosine pranobex and zidovudine metabolism. Lancet 1989; II: 977

    Article  Google Scholar 

  70. Knupp CA, Brater C, Relue J, et al. Pharmacokinetics of didanosine and ketoconazole after coadministration to patients seropositive for the human immunodeficiency virus. J Clin Pharmacol 1993; 33: 912–7

    PubMed  CAS  Google Scholar 

  71. Moreno F, Hardin TC, Rinaldi MG, et al. Itraconazole-didanos-ine excipient interaction. JAMA 1993; 269: 1508

    Article  PubMed  CAS  Google Scholar 

  72. Hardin TC, Sharkey-Mathis PK, Rinaldi MG, et al. Evaluation of the pharmacokinetic interaction between Itraconazole and didanosine in HIV-infected subjects [abstract no. A29]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1995 Sep 17–20; San Francisco

  73. Blum RA, D’Andrea DT, Florentino BM, et al. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med 1991; 114: 755–7

    PubMed  CAS  Google Scholar 

  74. Sadovski DC. Drug interactions with antiacids: mechanisms and clinical significance. Drug Saf 1994; 11: 395–407

    Article  Google Scholar 

  75. Opravil M, Joos B, Liithy R. Levels of dopsone and pyrimethamine in serum during once-weekly dosing for prophylaxis of pneumocystis carinii pneumonia and toxoplasmic encephalitis. Antimicrob Agents Chemother 1994; 38: 1197–9

    Article  PubMed  CAS  Google Scholar 

  76. Metroka CE, Me Mechan MF, Andrada R, et al. Failure of prophylaxis with dapsone in patients taking dideoxyinosine. N Engl J Med 1991; 325: 737

    PubMed  CAS  Google Scholar 

  77. Horowitz HW, Jorde UP, Wormaser GP. Drug interactions in use of dapsone for Pneumocystis carinii prophylaxis. Lancet 1992; 339: 747

    Article  PubMed  CAS  Google Scholar 

  78. Huengsberg M, Castelino S, Sherrard J, et al. Does drug interaction cause failure of PCP prophylaxis with dapsone? Lancet 1993; 341: 48

    Article  PubMed  CAS  Google Scholar 

  79. Sahai J, Garber G, Gallicano K, et al. Effect of didanosine (ddI) on dapsone (DAP) absorption in HIV-infected patients [abstract no. A32]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1995 Sep 17–20; San Francisco

  80. Sahai J, Gallicano K, Oliveras L, et al. Cations in the didanosine tablet reduce ciprofloxacin bioavailability. Clin Pharmacol Ther 1993; 53: 292–7

    Article  PubMed  CAS  Google Scholar 

  81. Lomaestro BM, Bailie GR. Absorption interactions with fluoroquinolones. Drug Saf 1995; 12: 314–33

    Article  PubMed  CAS  Google Scholar 

  82. Knupp CA, Graziano FM, Dixon RM, et al. Pharmacokinetic interaction study of didanosine and ranitidine in patients seropositive for human immunodeficiency virus. Antimicrob Agents Chemother 1992; 36: 2075–9

    Article  PubMed  CAS  Google Scholar 

  83. Gallicano K, Sahai H, Zaror-Behrens G, et al. Effect of antacids in didanosine tablet on bioavailability of isoniazid. Antimicrob Agents Chemother 1994; 38: 849–97

    Article  Google Scholar 

  84. Sahai J, Foss N, Li R, et al. Rifabutin and didanosine interaction in AIDS patients. Clin Pharmacol Ther 1993; 53: 197

    Article  Google Scholar 

  85. Knupp CA, Milbrath RL and Barbhaiya RH. Effect of metoclo-pramide and loperamide on the pharmacokinetics of didanosine in HIV seropositive asymptomatic male and female patients. Eur J Clin Pharmacol 1993; 45(5): 409–13

    Article  PubMed  CAS  Google Scholar 

  86. Brivet FG, Naveau SH, Lemaigre GF, et al. Pancreatic lesions in HIV-infected patients. Baillieres Clin Endocrinol Metab 1994; 8: 589–877

    Google Scholar 

  87. Massarella JW, Holazo AA, Koss-Twardy S, et al. The effects of cimetidine and Maalox® on the pharmacokinetics of zalcitabine in HIV-positive patients. Pharm Res 1994; 11: 415

    Google Scholar 

  88. Lee BL, Tauber MG, Chambers HF, et al. Zalcitabine (ddC) and dapsone (DAP) pharmacokinetic interaction in HIV-infected patients. Clin Pharmacol Ther 1995; 57: 186

    Google Scholar 

  89. Lee BL, Tauber MG, Chambers HF, et al. The effect of trimethoprim (TMP) on the pharmacokinetics (PK) of zalcitabine (ddC) in HIV infected patients [abstract no. A28]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1995 Sep 17–20; San Francisco

  90. Murray M. P450 enzymes; inhibition mechanisms, genetic regulation and effects of liver disease. Clin Pharmacokinet 1992; 23: 132–46

    Article  PubMed  CAS  Google Scholar 

  91. Moore K, Raasch R, Yuen G, et al. Pharmacokinetics of lamivudine administered alone and with oral trimethoprim plus sulfamethoxazole in patients with human immunodeficiency virus infection. Clin Pharmacol Ther 1995; 57: 143

    Google Scholar 

  92. Kempf D, Marsh K, Denissen J, et al. Coadministration with ritonavir enhances the plasma levels of HIV protease inhibitors by inhibition of cytochrome P450 [abstract no. 143]. 3rd Conference on retroviruses and opportunistic infections: 1996 Jan 28–Feb 1; Washington

  93. Israel BC, Blouin RA, McIntyre W, et al. Effect of interferon-α monotherapy on hepatic drug metabolism in cancer patients. Br J Clin Pharmacol 1993; 36: 229–35

    Article  PubMed  CAS  Google Scholar 

  94. Schiiller J, Czejka MJ, Banka S, et al. Continuous infusion of fluorouracil combined with interferon alfa 2B. Enhanced toxicity due to pharmacokinetic interaction. Ann Oncol 1994; 5: 48

    Google Scholar 

  95. Kellokumpu-Lehtinen P, Iisalo E, Nordman E. Hepatotoxicity of paracetamol in combination with interferon and vinblastine. Lancet 1989; I: 1143

    Article  Google Scholar 

  96. Lee BL, Safrin S. Drug interactions and toxicities in patients with AIDS. Curr Opin Infect Dis 1992; 5: 231–40

    Article  Google Scholar 

  97. Lee BL, Wong D, Benowitz NL, et al. Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome. Clin Pharmacol Ther 1993; 53: 529–35

    Article  PubMed  CAS  Google Scholar 

  98. Stretcher BN. Pharmacokinetic optimisation of antiretroviral therapy in patients with HIV infection. Clin Pharmacokinet 1995; 29: 46–65

    Article  PubMed  CAS  Google Scholar 

  99. Foulds G, Trapnell CB, Willavize SA, et al. Effect of concomitant azithromycin on the pharmacokinetics of zidovudine [abstract no. 2143]. 19th International Congress on Chemotherapy: 1995 Jul 16–21; Montreal

  100. Cooper D. Antiretroviral Therapy 96. Third conference on retroviruses and opportunistic infections: 1996 Jan 28–Feb 1; Washington

  101. Lange J. Combination antiretroviral therapy. Back to the future. Drugs 1995; 49: 32–7

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmacie, Hôpital Bicêtre, 78 Avenue du Général-Leclerc, 94275, Le Kremlin-Bicêtre Cedex, France

    Anne-Marie Taburet

  2. Hôpital Necker, Paris, France

    Eric Singlas

Authors
  1. Anne-Marie Taburet
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eric Singlas
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Taburet, AM., Singlas, E. Drug Interactions with Antiviral Drugs. Clin-Pharmacokinet 30, 385–401 (1996). https://doi.org/10.2165/00003088-199630050-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199630050-00005

Keywords

Search

Navigation